Search Results for "budesonide, oral"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for budesonide, oral. Results 11 to 16 of 16 total matches.
Elafibranor (Iqirvo) for Primary Biliary Cholangitis
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024 (Issue 1718)
to be approved
for this indication. Seladelpar (Livdelzi), an oral PPAR-delta
agonist, received accelerated ...
Elafibranor (Iqirvo – Ipsen), a peroxisome proliferator-activated
receptor (PPAR) agonist, has been granted
accelerated approval by the FDA for treatment of
primary biliary cholangitis (PBC) in adults. It is
indicated for use in combination with ursodeoxycholic
acid (ursodiol, UDCA; Urso, and others) in patients
with an inadequate response to UDCA alone and as
monotherapy in those unable to tolerate UDCA.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):202-4 doi:10.58347/tml.2024.1718b | Show Introduction Hide Introduction
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
Ozanimod (Zeposia) for Ulcerative Colitis
The oral sphingosine 1-phosphate (S1P) receptor ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025 (Issue 1725)
have a rapid onset of action
▶ Efficacy is equal or superior to
that of oral H1-antihistamines
Adverse ...
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Med Lett Drugs Ther. 2025 Mar 31;67(1725):e58-63 doi:10.58347/tml.2025.1725c | Show Introduction Hide Introduction
Seladelpar (Livdelzi) for Primary Biliary Cholangitis
The Medical Letter on Drugs and Therapeutics • Jan 20, 2025 (Issue 1720)
remain to be
determined.
or relieved pruritus in 96% of patients.4 Budesonide,
methotrexate ...
Seladelpar (Livdelzi – Gilead), a peroxisome
proliferator-activated receptor (PPAR)-delta agonist,
has received accelerated approval from the FDA for use
in combination with ursodeoxycholic acid (ursodiol,
UDCA; Urso Forte, and generics) for treatment of
primary biliary cholangitis (PBC) in adults who had an
inadequate response to UDCA and as monotherapy in
those unable to tolerate UDCA. Accelerated approval
was based on a reduction in alkaline phosphatase
(ALP) levels. Seladelpar is the second PPAR agonist
to be approved in the US for this indication; elafibranor
(Iqirvo)...
Med Lett Drugs Ther. 2025 Jan 20;67(1720):13-5 doi:10.58347/tml.2025.1720d | Show Introduction Hide Introduction
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
Oral Drugs for COPD .....................................................p 141
Treatment of COPD ...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 doi:10.58347/tml.2024.1710a | Show Introduction Hide Introduction
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025 (Issue 1725)
they are
intermittent or persistent (see Table 1).1
H1-ANTIHISTAMINES — Oral second-generation H1-antihistamines (see ...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56 doi:10.58347/tml.2025.1725a | Show Introduction Hide Introduction